Common mechanisms of oxidative damage in chronic neurodegenerative conditions: potential points of therapeutic intervention

Bibliography

• STADTMAN ER: Protein oxidation and ageing. Science(1992) 257:1220–1224.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, TATTON WG: Etiology and pathogenesisof Parkinson's disease. Ann. Rev. Neurosci. (1999) 22:123–144.
   PubMed Web of Science ®Google Scholar
• MARKESBERY WR: Oxidative stress hypothesis inAlzheimer's disease. Free Radic. Biol. Med. (1997) 23:134–147.
   PubMed Web of Science ®Google Scholar
• ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutationsin Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59–62.
   PubMed Web of Science ®Google Scholar
• ESTERBAUER H, SCHAUR RJ, ZOLLNER H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. (1991) 11:81–128.
   PubMed Web of Science ®Google Scholar
• ••Exceptional review of lipid peroxidation.
   Google Scholar
• MARK RJ, FUSON KS, MAY PC: Characterization of8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage. J. Neurochem. (1999) 72:1146–1153.
   PubMedGoogle Scholar
• MARK RJ, LOVELL MA, MARKESBERY WR et al: Evidencethat 4-hydroxynonenal mediates disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. (1997) 68:255–264.
   PubMed Web of Science ®Google Scholar
• MORROW JD, ROBERTS LJ: The isoprostanes: current knowledge and directions for future research. Biochem. Pharmacol. (1996) 15:1–9.
   Google Scholar
• •Review of 8-isoprostane field.
   Google Scholar
• JURGENS G, LANG J, ESTERBAUER H: Modification ofhuman low-density lipoprotein by the lipid peroxida-tion product 4-hydroxynonenal. Biochem. Biophys. Acta (1986) 875:103–114.
   PubMed Web of Science ®Google Scholar
• UCHIDA K, STADTMAN ER: Modification of histidineresidues in proteins by reaction with 4-hydroxynonenal. Proc. Natl. Acad Sci. USA (1992) 89:4544–4548.
   PubMed Web of Science ®Google Scholar
• SAYRE LM, ZELASKO DA, HARRIS PL et al.:4-Hydroxynonenal-derived advanced lipid peroxida-tion end products are increased in Alzheimer's disease. J. Neurochem. (1997) 68:2092–7.
   PubMed Web of Science ®Google Scholar
• YORITAKA A, HATTORI N, UCHIDA K et al: Immunohis-tochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA (1996) 93:2696–2701.
   PubMed Web of Science ®Google Scholar
• MOREL P, TALLINEAU C, PONTCHARRAUD R etal: Effectsof 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes. Neurochem. Int. (1998) 33:531–540.
   PubMedGoogle Scholar
• SANFELIU C, HUNT A, PATELL AJ: Exposure to N-methyl-n-aspartate increases release of arachidonic acid in primary cultures of rat hippocampal neurons and not in astrocytes. Brain Res. (1990) 526:241–248.
   PubMedGoogle Scholar
• VERITY MA: Mechanisms of phospholipase A2 activa-tion and neuronal injury. Ann. NY Acad. Sci. (1993) 679:110–120.
   PubMedGoogle Scholar
• LAFON-CAZAL M, PIETRI S, CUICASI M, BOCKAERT J:NMDA-dependent superoxide production and neurotoxicity. Lett. Nature (1993) 364:535–537.
   PubMed Web of Science ®Google Scholar
• ZHANG J, SNYDER SH: Nitric oxide in the nervoussystem. Ann. Rev. Pharmacol. Toxicol. (1995) 35:213–33.
   PubMed Web of Science ®Google Scholar
• BECKMAN JS, CHEN J, CROW JP, YE YZ: Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog. Brain Res. (1994) 103:371–380.
   PubMed Web of Science ®Google Scholar
• LIPTON SA: Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. (1993a) 16:527–532.
   PubMed Web of Science ®Google Scholar
• LIPTON SA: A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature (1993b) 364:626–632.
   PubMed Web of Science ®Google Scholar
• RADI R, BECKMAN JS, BUSH KM, FREEMAN BA: Peroxynitrite-induced membrane lipid peroxidation: the cytoplasmic peotential of superoxide and nitric oxide. Arch. Biochem. Biophys. (1991) 288:481–487.
   PubMed Web of Science ®Google Scholar
• KELLER JN, MATTSON MP Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev. Neurosci. (1998) 9:105–116.
   PubMed Web of Science ®Google Scholar
• •Good review of biological effects of common lipid peroxi-dation products.
   Google Scholar
• WEISS JH, PIKE CJ, COTMAN CW: Ca2+ channel blockers attenuate 8-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. (1994) 62:372–375.
   PubMed Web of Science ®Google Scholar
• BUSCIGLIO J, LORENZO A, YANKNER BA: Methodologi-cal variables in the assessment of beta amyloid neurotoxicity. Neurobiol. Aging (1992) 13:609–612.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, CHENG B, DAVIS D et al: 8-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Neurosci. (1992) 12:379–389.
   Google Scholar
• COX B, DENYER JC: N-Type calcium channel blockers in pain and stroke. Exp. Opin. Ther. Patents (1998) 8:1237–1250.
   Web of Science ®Google Scholar
• HANTRAYE P, BROUILLET E, FERRANTE R et al.: Inhibi-tion of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Merl. (1996) 2:1017–1021.
   PubMed Web of Science ®Google Scholar
• WOOD WG, IGBAVBOA AM, RAO F et al.: Cholesterol oxidation reduces Ca2+ + Mg2+-ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes. Brain Res. (1995) 683:36–42.
   PubMedGoogle Scholar
• MILLER B, SARANTIS M, TRAYNELIS FS et al: Potentiation of NMDA receptor currents by arachidonic acid. Nature (1992) 355:722–725.
   PubMed Web of Science ®Google Scholar
• HARMAN D: Free-radical theory of aging. Increasing the functional life span. Ann. NY Acad. Sci. (1994) 717:1–15.
   PubMed Web of Science ®Google Scholar
• ••Classic paper describing oxidative changes that occur withnormal ageing.
   Google Scholar
• BENZI G, MORETTI A: Age- and peroxidative stress-related modifications of the cerebral enzymatic activi-ties linked to mitochondria and the glutathione system. Free Radic. Biol. Med. (1995) 19:77–101.
   PubMed Web of Science ®Google Scholar
• ORR WC, SOHAL RS: The effects of catalase gene overex-pression on life span and resistance to oxidative stress in transgenic Drosophila melanogaster. Arch Biochem Biophys (1992) 297:35–41.
   PubMed Web of Science ®Google Scholar
• EDAMATSU R, MORI A, PACKER L: The spin-trap N-tert-alpha-phenyl-butylnitrone prolongs the life span of the senescence accelerated mouse. Biochem. Biophys. Res. Comm. (1995) 211:847–849.
   PubMed Web of Science ®Google Scholar
• SMITH CD, CARNEY JM, STARKE-REED PE et al.: Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1991) 88:10540–10543.
   PubMed Web of Science ®Google Scholar
• CARRILLO MC, KANAI S, SATO Y, KITANI K: Age-related changes in antioxidant enzyme activities are region and organ, as well as sex, selective in the rat. Mech. Ageing Dev. (1992) 65:187–198.
   PubMedGoogle Scholar
• CARNEY JM, STARKE-REED PE, OLIVER CN et al: Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. USA (1991) 88:3633–3636.
   PubMed Web of Science ®Google Scholar
• •Paper demonstrating utility of spin-trapping compounds in attenuating the cumulative oxidative damage and cognitive impairment that occurs with normal ageing.
   Google Scholar